In a recent transaction on March 20, 2024, Director Rahul Ballal of Enliven Therapeutics Inc (NASDAQ:ELVN) sold 13,278 shares of the company's stock, according to a SEC Filing.
/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.
Mediar Therapeutics raises $85 million to develop drugs for diseases that cause scarring in organs; Bellicum Pharmaceuticals halted its Phase I/II trials after a serious adverse event; The Food and Drug Administration says Paxlovid is not associated with COVID rebound.
The Series A round was co-led by Novartis Venture Fund and Sofinnova Partners and has seen participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli